Brainsway Dtms denied as experimental or investigational by Humana?

Humana's specific coverage criteria for brainsway dtms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny BrainsWay Deep TMS as Experimental

An "experimental or investigational" denial from Humana means the plan has determined that the evidence base for BrainsWay Deep TMS does not yet meet its internal threshold for established clinical benefit. This is one of the most commonly challenged denial categories because FDA clearance and evolving professional-society guidance frequently outpace insurer policy update cycles.

BrainsWay Deep TMS holds FDA 510(k) clearance for specific psychiatric indications. FDA clearance does not automatically translate to insurer coverage, but it is a foundational rebuttal to an "experimental" label. Your appeal should document the regulatory and clinical-evidence landscape directly.

## Federal Appeal Framework

• ACA §2719 / External Review: Independent external review is your most powerful lever for experimental denials. External reviewers apply clinical standards independently of Humana's internal criteria. File within approximately 4 months (180 days) of the denial. Expedited review is available for urgent clinical situations.
• ERISA §503: If this is an employer-sponsored plan, you are entitled to a full-and-fair review, including access to all criteria and clinical guidelines Humana relied upon.

## Appeal Process and Timeline

1. Obtain the denial rationale in full — request the specific clinical criteria and any guidelines Humana cited to classify Deep TMS as experimental. 2. Internal appeal — respond point-by-point to each basis cited. Standard turnaround is up to 30 days; urgent cases qualify for 72-hour review. 3. External review — particularly valuable here; independent physician reviewers frequently overturn experimental denials where FDA clearance exists and professional guidelines support use.

## Documentation to Gather

• FDA clearance documentation: The 510(k) clearance letter or summary for BrainsWay Deep TMS covering the relevant indication.
• Professional-society guideline support: A statement from the prescriber referencing the applicable guideline organization (e.g., relevant psychiatric or neurology society) that recognizes this treatment for the diagnosed condition.
• Diagnosis and severity documentation: Chart notes, validated rating scales, and clinical assessment demonstrating the condition and its impact.
• Prior treatment failure history: Dates, durations, and outcomes of all previous treatments tried—showing that established alternatives were exhausted.
• Prescriber medical-necessity letter: Detailed clinical rationale explaining why this treatment is appropriate and not experimental for this specific patient.

## Criteria-Mapping Structure

Pull Humana's current published medical/coverage policy and work through each experimental criterion:

| Humana Experimental Criterion | Your Rebuttal Evidence | |---|---| | FDA approval/clearance status | [FDA 510(k) clearance for this indication] | | Evidence-base adequacy per policy | [Prescriber summary of guideline support] | | Diagnosis and indication match | [Chart documentation of confirmed diagnosis] | | Prior standard-of-care attempts | [Treatment history with dates and outcomes] |

Verify the exact current version of Humana's Deep TMS coverage policy before filing. Policy language changes, and citing an outdated version weakens the appeal.